Posts

Shionogi to acquire IntraBio for $2 billion, expanding rare-disease portfolio

on
Shionogi agreed to acquire Austin-based IntraBio for $2 billion upfront, buying all outstanding shares. The deal would make IntraBio a wholly owned subsidiary of Shionogi’s U.S. arm. The centerpiece is AQNEURSA (levacetylleucine), for which Shionogi would gain global intellectual-property and commercialization rights. It is approved for neurological symptoms of Niemann-Pick disease type C and, more recently, ataxia associated with ataxia-telangiectasia. Shionogi says IntraBio’s rare-disease expertise and pipeline—including programs in Pompe disease, Fragile X syndrome, and Jordan’s syndrome—will strengthen its expansion into rare neurological conditions. The agreement is subject to customary closing conditions and regulatory clearances. Shionogi expects completion between November and December 2026. The acquisition continues Shionogi’s push to grow beyond its traditional infectious-disease focus and build out a rare-disease business. Sources: Shionogi Continues Rare Disease...

Three biotechs move toward IPOs as Lycia targets antibody degradation

on

Abbott wins FDA approval for patient-facing CardioMEMS features

on

Are physicians ready to embrace digital twins?

on

Rewind Therapeutics raises additional financing for oral remyelination program

on

Lilly expands Gate Bioscience deal with more than $870 million in potential payments

on

Candel Therapeutics to Present Two Posters at SITC 2026

on

RAG-18 shows early target engagement in a three-person DMD cohort

on

Vaxcyte shares surge after positive Phase 3 vaccine results

on

FDA extends review of Novo’s hemophilia A drug over factory remediation

on

Genentech licenses Alector’s preclinical Parkinson’s candidate for $100 million upfront

on

CSL and Alentis strike up to US$1.6 billion drug-development deal

on

Recent pharma deals: AstraZeneca backs ivonescimab

on